Fiber Fusion Splicer Features System Auto Test

Toronto, Canada – GAO Comm (www.GAOComm.com) is offering its fiber fusion splicer which features system auto test ensuring the best outcome based on operating conditions. It is designed for single mode fiber, multi-mode fiber, dispersion-shifted fiber (DSF), non-zero dispersion-shifted fiber (NZ-DSF) and erbium-doped fiber (EDF). This compact fiber fusion splicer, model C0210001, offers both manual and automatic splicing modes. The single fiber fusion splicer features simultaneous X and Y views, a short splicing time of eight seconds and an impressive tube heating time (sleeve shrinking time) of 40 seconds. It detects the fiber end-face and adjusts parameters automatically. It can store 8000 groups of splice records. The splicer has a reversible monitor with control panel on each side. The single fiber fusion splicer automatically adjusts to environmental conditions using built-in temperature, humidity and pressure sensors which provide constant feedback signals to control the fusion arc temperature. This compact fiber fusion splicer is an ideal tool for construction and maintenance of fiber and cable in both field and laboratory applications. This fiber fusion splicer belongs to GAO’s family of Fusion Splicers. Another product in this line is Digital Fiber Fusion Splicer which is an ideal tool for construction and maintenance of fiber and cable in both field and laboratory applications. GAO Comm provides various optical and electrical equipment and test instruments for use in telecommunications, CATV, power industry and for science and research. For sales inquiries please contact: 1-877 585-9555 ext. 601 – Toll Free (USA & Canada) 1-416 292-0038 ext. 601 – All Other Areas [email protected] About GAO Comm GAO Comm Inc. (www.GAOComm.com) is a well-known supplier of optical and electrical equipment and test instruments which are widely used in Telecommunications, CATV, Power industry and for Science and Research.

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.